Cas:384842-25-5 ditert-butyl(1,1-diphenylprop-1-en-2-yl)phosphane manufacturer & supplier

Chemical Name:ditert-butyl(1,1-diphenylprop-1-en-2-yl)phosphane

CAS.NO:384842-25-5

Synonyms:vBRIDP;Bis(1,1-dimethylethyl)(1-methyl-2,2-diphenylethenyl)phosphine;Di-tert-butyl(1-methyl-2,2-diphenylethenyl)phosphine;1,1-diphenyl-2-(di-tert-butylphosphino)propene

Molecular Formula:C₂₃H₃₁P

Molecular Weight:338.46600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:13.59000

Exact Mass:338.21600

LogP:7.54480

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like vBRIDP chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,1-diphenyl-2-(di-tert-butylphosphino)propene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Bis(1,1-dimethylethyl)(1-methyl-2,2-diphenylethenyl)phosphine Use and application,1,1-diphenyl-2-(di-tert-butylphosphino)propene technical grade,usp/ep/jp grade.

Related News: The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. ditert-butyl(1,1-diphenylprop-1-en-2-yl)phosphane manufacturer The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. ditert-butyl(1,1-diphenylprop-1-en-2-yl)phosphane supplier Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. ditert-butyl(1,1-diphenylprop-1-en-2-yl)phosphane vendor The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market. ditert-butyl(1,1-diphenylprop-1-en-2-yl)phosphane factory ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.